APTAMER GROUP PLC - Interim Results

Aptamer Group PLC’s Interim Results for the six months to 31 December 2025 highlighted solid commercial momentum, with revenue rising 27% to £0.83 million, supported by strong fee-for-service activity, major pharma contract wins and a £2 million order book. The biotech company reported a £3.1 million sales pipeline, stable operating costs, and a modest improvement in EBITDA loss, while maintaining £1.5 million in cash at period end. Management emphasized progress in shifting the business model toward higher-value, recurring revenue streams through licensing, royalties and supply income, including two royalty-bearing licensing deals signed in December 2025. Aptamer also outlined growth across its expanding asset portfolio, with developments in radiopharmaceuticals, liver fibrosis delivery, diagnostics and consumer health, alongside continued investment in manufacturing and platform capability. Looking ahead, the group plans to accelerate preclinical programmes, expand licensing activity and integrate AI and machine learning into its discovery platform to improve hit rates, shorten development timelines, enhance margins and strengthen its position in oligonucleotide therapeutics and hard-to-drug targets. Overall, the interim investor update presents Aptamer Group as a growth-focused biotech advancing revenue, broadening its order book and building long-term shareholder value through commercial execution and platform innovation.